Inclisiran
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Inclisiran and local guidelines before prescribing.
siRNA lipid-lowering agent
Mechanism
Small interfering RNA reducing hepatic PCSK9 synthesis.
Uses
Hypercholesterolaemia above target on maximum tolerated statin.
Dosing
- If the target is not met: Add ezetimibe 10 mg daily, then consider other NICE-approved options (e.g. inclisiran, PCSK9 inhibitors).
Cardiology: Ischaemic Heart Disease (ACS) - Secondary prevention: atorvastatin 80 mg (lower dose if interactions or CKD); lipid-lowering targets LDL ≤2.0 mmol/L or non-HDL ≤2.6 mmol/L; add ezetimibe, then inclisiran or a PCSK9 inhibitor if criteria are met.
General Practice: Long-term conditions, multimorbidity and polypharmacy
Side effects
Injection-site reactions, arthralgia, bronchitis.
Interactions
Few.
Contraindications and cautions
Hypersensitivity
Monitoring
Lipids
Pregnancy and breastfeeding
Avoid
Renal and hepatic impairment
No adjustment
Overdose and reversal
Supportive
Special advice
Twice-yearly injection after initial doses; used per NICE criteria.
More from the textbook: uses, cautions and other points
- PCSK9 inhibitors - alirocumab , evolocumab (injections every 2–4 weeks); inclisiran (small interfering RNA, injection every 6 months) - large LDL reductions for high-risk or familial hypercholesterolaemia patients not at target.
Cardiology: Anatomy Physiology and Pharmacology - Ezetimibe / inclisiran / PCSK9 inhibitors | Additional LDL lowering.
Cardiology: Anatomy Physiology and Pharmacology - True intolerance of all statins is uncommon. If it occurs, use ezetimibe, bempedoic acid or inclisiran.
Endocrinology: Lipids and obesity - Inclisiran | SC at 0, 3 months, then 6-monthly. CVD with LDL 2.6 or more despite maximum statin (NICE TA733).
Endocrinology: Lipids and obesity - He meets NICE TA733 for inclisiran (CVD with LDL 2.6 or more on maximum tolerated treatment). A PCSK9 antibody is an alternative.
Endocrinology: Lipids and obesity - Secondary prevention target: LDL 2.0 or less, or non-HDL 2.6 or less. Add ezetimibe, then inclisiran or a PCSK9 inhibitor.
Endocrinology: Lipids and obesity - Normal or mildly raised CK - consider a break and re-challenge, a lower dose, or a different statin. Don't abandon lipid lowering - consider ezetimibe, bempedoic acid or inclisiran.
Neurology: Neuromuscular disease - PCSK9 inhibitors (evolocumab, alirocumab) or inclisiran if LDL remains high (NICE criteria); bempedoic acid in some.
Clinical Genetics: Cancer genetics and inherited cardiovascular conditions
Where it is discussed in the book
- Cardiology: Anatomy Physiology and Pharmacology (2 mentions)
- Cardiology: Ischaemic Heart Disease (ACS) (1 mention)
- Endocrinology: Lipids and obesity (4 mentions)
- Neurology: Neuromuscular disease (1 mention)
- Clinical Genetics: Cancer genetics and inherited cardiovascular conditions (2 mentions)
- Integrated cardiology chapter (1 mention)
- General Practice: Long-term conditions, multimorbidity and polypharmacy (1 mention)
- Biochemistry: Metabolism of carbohydrates, lipids and proteins (1 mention)
- Cell Biology: Molecular biology, gene expression and laboratory techniques (1 mention)